Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: An add-on open study

International Clinical Psychopharmacology

Volumn 14, Issue 2, 1999, Pages 95-100

  Poyurovsky, M ^a   Isakov, V ^b   Hromnikov, S ^b   Modai, I ^b   Rauchberger, B ^b   Schneidman, M ^a   Weizman, A ^c  

^a Technion Medical School   (Israel)

^b Shaar Menashe Psychiatric Hospital   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

Author keywords

Adjunctive treatment; Fluvoxamine; Obsessive compulsive symptoms; Schizophrenia; Serotonin selective reuptake inhibitor

Indexed keywords

CARBAMAZEPINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; PERPHENAZINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGGRESSIVENESS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; OBSESSION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0032984116     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199903000-00006     Document Type: Article

References (37)

1. Andreasen NC (1983). Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa.
2. Andreasen NC (1984). Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, University of Iowa.
3. Bark N, Lindenmayer JP (1992). Ineffectiveness of clomipramine for obsessive-compulsive symptoms in a patient with schizophrenia (letter). Am J Psychiatry 149:136-137.
4. Barnes TRE (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-6.
5. Berman I, Kalinowski A, Berman S, Lengua J, Green A (1995a). Obsessive-compulsive symptoms in chronic schizophrenia. Comp Psychiatry 36:6-10.
6. Berman I, Sapers BL, Chang HHJ, Losonczy MF, Schmildler J, Green AI (1995b). Treatment of obsessive - compulsive symptoms in schizophrenic patients with clomipramine. J Clin Psychopharmacol 15:206-210.
7. Berman 1, Merson A, Viegner B, Losnoczy MF, Pappas D, Green AJ (1998), Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: a neuropsychological study. J Nervous Mental Dis 186:150-156.
8. Eisen JL, Beer DA, Pato MT, Venditto TA, Rasmussen SA (1997). Obsessive-compulsive disorder in patients with schizophrenia and schizoaffective disorder. Am J Psychiatry 154:271-273.
9. Evins AE, Goff DC (1996). Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. CNS Drugs 6:130-147.
10. Fenton WS, McGlashan TH (1986). The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry 143:437-441.
11. First MB, Spitzer RL, Gibbon M, Williams JBW (1995). Structured Clinical Interview far Axis I DSM-IV Disorders - Patient Edition(SCID-I/P, Version 2). New York: Biometrics Research Department, New York State Psychiatric Institute.
12. Goff DC, Midha KK, Brotman AW, Waites M, Baldessarini RY (1991). Elevation of plasma concentrations of haloperidol after addition of fluoxetine. Am J Psychiatry 148:790-792.
13. Goodman WK, Price LH, Rasmussen SA, Mazure K, Fleischmann RL, Hill CI, et al. (1989). The Yale-Brown Obsessive-Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 46:1006-1011.
14. Greist JII (1990). Treating the anxiety: therapeutic options in obsessive compulsive disorder. J Clin Psychiatry 51(11) Suppl):24-26.
15. Guy W (1976). ECDEV Assessment Manual for Psychopharmacology, revised edn, Washington DC: US Department of Health, Education and Welfare.
16. Hamilton MA (1960). A rating scale for depression. J Neurol Nenrosurg Psychiatry 23:56-62.
17. Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H (1994). Elevated serum levels of clozapine after addition of fluvoxamine. J Clin Psychopharmacol 14:279-281.
18. Howland RH (1996). Chlorpromazine and obsessive-compulsive symptoms (letter). Am J Psychiatry 153:1503.
19. Hwang MY, Opler LA (1994). Schizophrenia with obsessive-compulsive features: assessment and treatment. Psychiatr Ann 24:468-472.
20. Iida J, Iwasaka H, Hirao F, 1 Hasino K, Matsumura K, Tahar K et al. ( 1995). Clinical features of childhood-onset schizophrenia with obsessive-compulsive symptoms during the prodromal phase. Psychiatry Clin Neurosci 49:201-207.
21. Kopala L, Honer WG (1994). Risperidone, scrotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia (letter). Am J Psychiatry 151:1714-1715.
22. Kramer MS, Vogel WH, DiJohnson C, Dewey DA, Sheves P, Cavicchia S et al. (1989). Antidepressants in 'depressed' schizophrenic inpatients: a controlled trial. Arch Gen Psychiatry 46:922-928.
23. Lindenmayer UP, Vakharia M, Kanorsky D (1990). Fluoxetine in chronic schizophrenia (letter). J Clin Psychopharmacol 1:76.
24. Patil VJ (1992). Development of transient compulsive symptoms during treatment with clozapine (letter). Am J Psychiatry 149:272.
25. Porto L, Bermanzohn PC, Pollack S, Morrissey R, Siris S (1997). A profile of obsessive-compulsive symptoms in schizophrenia. CNS Spectrums 2:21-25.
26. Poyurovsky M, Hermesh H, Weizman A (1996a). Fluoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenia patients. Clin Neuropharmacol 19:305-313.
27. Poyurovsky M, Meerovich I, Weizman A (1996b). Beneficial effect of low-dose mianserin on fluvoxamine-induced akathisia in an obsessive-compulsive patient. Int Clin Psychopharmacol 11:61-66.
28. Poyurovsky M, Schneidman M, Weizman A (1997). Successful treatment of fluoxetine-induced dystonia with low-dose mianserin. Movement Dis 12:11U2-1105.
29. Poyurovsky M, Weizman A (1997). Beneficial effect of clozapine in schizophrenic patients with comorbid obsessive-compulsive symptoms. In: American Psychiatric Association Annual Meeting San Diego, CA, May. p. 136.
30. Poyurovsky M, Weizman A (1998). Intravenous clomipramine for a schizophrenic patient with obsessive -compulsive disorder (letter). Am J Psychiatry 155:993.
31. Silver H, Kaplan A, Kushnir M (1995). Fluvoxamine augmentation in chronic schizophrenia: an open exploratory study. Hitman Psychopharmacol 10:59-63.
32. Simpson GM, Angus JWS(1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212(suppl):11-19.
33. Strobel CF, Szarck BL, Glueck BC(1984). Use of clomipramine in treatment of obsessive compulsive symptomatology. J Clin Psychopharmacol 4:8-100.
34. Von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz HS, Shader I (1995). Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin Psychopharmacol 15:125-132.
35. Wykes T, Sturt E (1986). The measurement of social behaviour in psychiatric patients: an assessment of the reliability and validity of the SBS schedule. Br J Psychiatry 148:1-11.
36. Yaryura-Tobias JA, Neziroglu MA, Bergman L (1976). Clomipramine for obsessive-compulsive neurosis: an organic approach. Curr Ther Res 20:541-548.
37. Zohar J, Kaplan Z, Benjamin J (1993). Clomipramine treatment of obsessive-compulsive symptomatology in schizophrenic patients. J Clin Psychiatry 54:385-388.